MX2023005501A - Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. - Google Patents

Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.

Info

Publication number
MX2023005501A
MX2023005501A MX2023005501A MX2023005501A MX2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A
Authority
MX
Mexico
Prior art keywords
inhibitors
cdk4
cancer
combinations
treatment
Prior art date
Application number
MX2023005501A
Other languages
English (en)
Spanish (es)
Inventor
James Shanahan
Peter Cornelius
Bradley J Carver
Original Assignee
Syndevrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndevrx Inc filed Critical Syndevrx Inc
Publication of MX2023005501A publication Critical patent/MX2023005501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023005501A 2020-11-11 2021-11-10 Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. MX2023005501A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112217P 2020-11-11 2020-11-11
US202163166060P 2021-03-25 2021-03-25
PCT/US2021/058775 WO2022103834A1 (en) 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2023005501A true MX2023005501A (es) 2023-07-27

Family

ID=78821168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005501A MX2023005501A (es) 2020-11-11 2021-11-10 Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.

Country Status (8)

Country Link
US (1) US20230404963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4243807A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023550035A (cg-RX-API-DMAC7.html)
KR (1) KR20230117574A (cg-RX-API-DMAC7.html)
AU (1) AU2021378944A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198173A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005501A (cg-RX-API-DMAC7.html)
WO (1) WO2022103834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
EP4568706A1 (en) * 2022-08-10 2025-06-18 Syndevrx, Inc. Metap2 inhibitors for the treatment of pulmonary fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20130137831A1 (en) * 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
AU2017206718B2 (en) * 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US11612577B2 (en) * 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof
WO2023178255A1 (en) * 2022-03-16 2023-09-21 Syndevrx, Inc. Combinations comprising metap2 inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
WO2022103834A1 (en) 2022-05-19
CA3198173A1 (en) 2022-05-19
US20230404963A1 (en) 2023-12-21
AU2021378944A1 (en) 2023-06-15
KR20230117574A (ko) 2023-08-08
EP4243807A1 (en) 2023-09-20
JP2023550035A (ja) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2021009563A (es) Combinacion farmaceutica que comprende tno155 y ribociclib.
MX2025003445A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
MX2022004513A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
EP4249000A3 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
MX2021009562A (es) Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
JOP20220167A1 (ar) مثبطات sarm1
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
MX2023013912A (es) Metodos para inhibir ras.
MX2024008115A (es) Tratamiento conjunto para tratamiento contra el cancer.
AU2018238202A8 (en) Combination therapy for the treatment or prevention of tumours
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX395085B (es) Tratamiento conjunto contra tipos de cancer hematologico.
WO2024006292A3 (en) Methods of treating cancer
PH12021552147A1 (en) Rad51 inhibitors
WO2024163641A3 (en) Formulations for treating cancer
MX2022013867A (es) Combinacion farmaceutica que comprende tno155 y nazartinib.
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2025013034A (es) Inhibidores de egfr para el tratamiento de enfermedades